PBH Valuation

Prestige Consumer Healthcare Inc

Add to Watchlist

Advanced Chart

66.910

+0.41(0.617%)1D

Overview
Forecast
Valuation
Earnings

PBH Relative Valuation

PBH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PBH is overvalued; if below, it's undervalued.

Historical Valuation

Prestige Consumer Healthcare Inc (PBH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 14.54 is considered Undervalued compared with the five-year average of 14.27. The fair price of Prestige Consumer Healthcare Inc (PBH) is between 78.48 to 91.67 according to relative valuation methord. Compared to the current price of 66.79 USD , Prestige Consumer Healthcare Inc is Undervalued By 14.9%.

Relative Value

Fair Zone

78.48-91.67

Current Price：66.79

14.9%

Undervalued

14.54

Trailing

Forward

11.52

EV/EBITDA

Prestige Consumer Healthcare Inc. (PBH) has a current EV/EBITDA of 11.52. The 5-year average EV/EBITDA is 11.59. The thresholds are as follows: Strongly Undervalued below 9.82, Undervalued between 9.82 and 10.70, Fairly Valued between 12.47 and 10.70, Overvalued between 12.47 and 13.36, and Strongly Overvalued above 13.36. The current Forward EV/EBITDA of 11.52 falls within the Historic Trend Line -Fairly Valued range.

12.53

EV/EBIT

Prestige Consumer Healthcare Inc. (PBH) has a current EV/EBIT of 12.53. The 5-year average EV/EBIT is 12.74. The thresholds are as follows: Strongly Undervalued below 10.86, Undervalued between 10.86 and 11.80, Fairly Valued between 13.69 and 11.80, Overvalued between 13.69 and 14.63, and Strongly Overvalued above 14.63. The current Forward EV/EBIT of 12.53 falls within the Historic Trend Line -Fairly Valued range.

3.00

Prestige Consumer Healthcare Inc. (PBH) has a current PS of 3.00. The 5-year average PS is 2.72. The thresholds are as follows: Strongly Undervalued below 1.82, Undervalued between 1.82 and 2.27, Fairly Valued between 3.18 and 2.27, Overvalued between 3.18 and 3.63, and Strongly Overvalued above 3.63. The current Forward PS of 3.00 falls within the Historic Trend Line -Fairly Valued range.

11.67

P/OCF

Prestige Consumer Healthcare Inc. (PBH) has a current P/OCF of 11.67. The 5-year average P/OCF is 11.41. The thresholds are as follows: Strongly Undervalued below 7.71, Undervalued between 7.71 and 9.56, Fairly Valued between 13.26 and 9.56, Overvalued between 13.26 and 15.11, and Strongly Overvalued above 15.11. The current Forward P/OCF of 11.67 falls within the Historic Trend Line -Fairly Valued range.

12.31

P/FCF

Prestige Consumer Healthcare Inc. (PBH) has a current P/FCF of 12.31. The 5-year average P/FCF is 12.08. The thresholds are as follows: Strongly Undervalued below 8.54, Undervalued between 8.54 and 10.31, Fairly Valued between 13.86 and 10.31, Overvalued between 13.86 and 15.63, and Strongly Overvalued above 15.63. The current Forward P/FCF of 12.31 falls within the Historic Trend Line -Fairly Valued range.

Prestige Consumer Healthcare Inc (PBH) has a current Price-to-Book (P/B) ratio of 1.76. Compared to its 3-year average P/B ratio of 2.03 , the current P/B ratio is approximately -13.29% higher. Relative to its 5-year average P/B ratio of 1.92, the current P/B ratio is about -8.33% higher. Prestige Consumer Healthcare Inc (PBH) has a Forward Free Cash Flow (FCF) yield of approximately 8.00%. Compared to its 3-year average FCF yield of 7.13%, the current FCF yield is approximately 12.22% lower. Relative to its 5-year average FCF yield of 7.97% , the current FCF yield is about 0.41% lower.

1.76

P/B

Median3y

2.03

Median5y

1.92

8.00

FCF Yield

Median3y

7.13

Median5y

7.97

Competitors Valuation Multiple

The average P/S ratio for PBH's competitors is 5.71, providing a benchmark for relative valuation. Prestige Consumer Healthcare Inc Corp (PBH) exhibits a P/S ratio of 2.93, which is -48.64% above the industry average. Given its robust revenue growth of -6.59%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PBH.N

Prestige Consumer Healthcare Inc

Apellis Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

MoonLake Immunotherapeutics

Loss

3.82B

SLNO.O

Soleno Therapeutics Inc

13.09

3.56B

Performance Decomposition

Market capitalization of PBH decreased by 7.77% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 18.37 to 19.02.

The secondary factor is the P/E Change, contributed -4.72%to the performance.

Overall, the performance of PBH in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-6.59%

267.14M → 249.53M

Revenue Growth

3.54%

18.37 → 19.02

Margin Expansion

-4.72%

16.38 → 15.61

P/E Change

-7.77%